BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

673 related articles for article (PubMed ID: 29443372)

  • 1. Impact of Reticulated Platelets on the Antiplatelet Effect of the Intravenous P2Y12-Receptor Inhibitor Cangrelor.
    Stratz C; Nührenberg T; Valina CM; Löffelhardt N; Mashayekhi K; Ferenc M; Trenk D; Neumann FJ; Hochholzer W
    Thromb Haemost; 2018 Feb; 118(2):362-368. PubMed ID: 29443372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized Comparison of Oral P2Y
    Hochholzer W; Kleiner P; Younas I; Valina CM; Löffelhardt N; Amann M; Bömicke T; Ferenc M; Hauschke D; Trenk D; Neumann FJ; Stratz C
    JACC Cardiovasc Interv; 2017 Jan; 10(2):121-129. PubMed ID: 28104204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis.
    Westman PC; Lipinski MJ; Torguson R; Waksman R
    Cardiovasc Revasc Med; 2017 Mar; 18(2):79-85. PubMed ID: 28089137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamic effects during the transition between cangrelor and ticagrelor.
    Schneider DJ; Agarwal Z; Seecheran N; Keating FK; Gogo P
    JACC Cardiovasc Interv; 2014 Apr; 7(4):435-42. PubMed ID: 24656538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients.
    Rollini F; Franchi F; Tello-Montoliu A; Patel R; Darlington A; Ferreiro JL; Cho JR; Muñiz-Lozano A; Desai B; Zenni MM; Guzman LA; Bass TA; Angiolillo DJ
    JACC Cardiovasc Interv; 2014 Apr; 7(4):426-34. PubMed ID: 24630878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
    Franchi F; Rollini F; Rivas A; Wali M; Briceno M; Agarwal M; Shaikh Z; Nawaz A; Silva G; Been L; Smairat R; Kaufman M; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Bass TA; Angiolillo DJ
    Circulation; 2019 Apr; 139(14):1661-1670. PubMed ID: 30630341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transition strategies from cangrelor to oral platelet P2Y12 receptor antagonists.
    Schneider DJ
    Coron Artery Dis; 2016 Jan; 27(1):65-9. PubMed ID: 26444255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y(12) antagonists in an ex-vivo canine model.
    Ravnefjord A; Weilitz J; Emanuelsson BM; van Giezen JJ
    Thromb Res; 2012 Oct; 130(4):622-8. PubMed ID: 22909827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cangrelor inhibits the binding of the active metabolites of clopidogrel and prasugrel to P2Y12 receptors in vitro.
    Judge HM; Buckland RJ; Jakubowski JA; Storey RF
    Platelets; 2016; 27(3):191-5. PubMed ID: 26270719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversibility of platelet P2Y12 inhibition by platelet supplementation: ex vivo and in vitro comparisons of prasugrel, clopidogrel and ticagrelor.
    Bertling A; Fender AC; Schüngel L; Rumpf M; Mergemeier K; Geißler G; Sibrowski W; Kelsch R; Waltenberger J; Jakubowski JA; Kehrel BE
    J Thromb Haemost; 2018 Jun; 16(6):1089-1098. PubMed ID: 29582544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of P2Y
    Spinthakis N; Farag M; Gue YX; Srinivasan M; Wellsted DM; Gorog DA
    Thromb Res; 2019 Jan; 173():102-108. PubMed ID: 30500673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
    Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
    Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of immature platelets on platelet response to ticagrelor and prasugrel in patients with acute coronary syndrome.
    Bernlochner I; Goedel A; Plischke C; Schüpke S; Haller B; Schulz C; Mayer K; Morath T; Braun S; Schunkert H; Siess W; Kastrati A; Laugwitz KL
    Eur Heart J; 2015 Dec; 36(45):3202-10. PubMed ID: 26216931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of reticulated platelets on antiplatelet response to thienopyridines is independent of platelet turnover.
    Stratz C; Nührenberg T; Amann M; Cederqvist M; Kleiner P; Valina CM; Trenk D; Neumann FJ; Hochholzer W
    Thromb Haemost; 2016 Oct; 116(5):941-948. PubMed ID: 27487961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensified P2Y12 inhibition for high-on treatment platelet reactivity.
    Mshelbwala FS; Hugenberg DW; Kreutz RP
    J Thromb Thrombolysis; 2020 Oct; 50(3):619-627. PubMed ID: 32152791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function.
    Dovlatova NL; Jakubowski JA; Sugidachi A; Heptinstall S
    J Thromb Haemost; 2008 Jul; 6(7):1153-9. PubMed ID: 18485086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor.
    Gerrits AJ; Jakubowski JA; Sugidachi A; Michelson AD; Frelinger AL
    J Thromb Haemost; 2017 May; 15(5):858-867. PubMed ID: 28092426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cangrelor Use Patterns and Transition to Oral P2Y
    Rymer JA; Bhatt DL; Angiolillo DJ; Diaz M; Garratt KN; Waksman R; Edwards L; Tasissa G; Salahuddin K; El-Sabae H; Dell'Anna C; Davidson-Ray L; Washam JB; Ohman EM; Wang TY
    J Am Heart Assoc; 2022 Jun; 11(11):e024513. PubMed ID: 35621210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombus remodelling by reversible and irreversible P2Y
    Tunströmer K; Faxälv L; Larsson P; Lindahl TL; Boknäs N
    Platelets; 2023 Dec; 34(1):2157805. PubMed ID: 36631918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cangrelor versus Ticagrelor in Patients Treated with Primary Percutaneous Coronary Intervention: Impact on Platelet Activity, Myocardial Microvascular Function and Infarct Size: A Randomized Controlled Trial.
    Ubaid S; Ford TJ; Berry C; Murray HM; Wrigley B; Khan N; Thomas MR; Armesilla AL; Townend JN; Khogali SS; Munir S; Martins J; Hothi SS; McAlindon EJ; Cotton JM
    Thromb Haemost; 2019 Jul; 119(7):1171-1181. PubMed ID: 31129911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.